Home

Heart Failure

HFO 2022 - Session 1.2 Practical Theory & Hot Topics: The Complex Patient

1.00 EBAC

Published: 01/06/2022

Select foundational and advanced management strategies in complex patients
Discuss the validity of using ejection fraction to determine optimal treatment strategies
Assess the likely impact of health technology on future practice
Identify the underlying causes of heart failure
Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
Assess the impact of the multidisciplinary team on heart failure outcomes
Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points

Hypertrophic Cardiomyopathy: Application of Emerging Data and Genetic Testing in Clinical Practice

Carolyn Ho

0.75 AMA PRA Credit

Published: 17/02/2022

Recall the efficacy and safety of existing HCM treatments
Summarise results from ongoing trials with experimental treatments
Stratify individuals with HCM signs and symptoms for subsequent investigation and/or genetic screening

Hypertrophic Cardiomyopathy in Review: Highlights from HFA 2021

Perry Elliott

0.50 AMA PRA Credit

Published: 04/11/2021

Identify patients likely to benefit from invasive procedures versus pharmacological treatment
Stratify individuals with HCM signs and symptoms for subsequent investigation and/or genetic screening

Heart Failure

SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure

Scott Solomon John JV McMurray Carolyn Lam et al

1.00 EBAC

Published: 08/09/2022

Recall the results of key trials in HFmrEF in different patients' sub-groups
Describe how SGLT-2 inhibitors can be used across the range of LVEF
Apply emerging diagnostic approaches for HFpEF and HFmrEF
Implement best-practice strategies across the range of LVEF

The 2022 ACC HF Guidelines: What Do They Mean for Your Practice?

Not accredited

Published: 09/06/2022

Summarise the main updates to the 2022 ACC heart failure (HF) guidelines
Compare updates from the ACC with the 2021 ESC HF guidelines
Recall guideline recommendations for the initiation of foundational therapy for heart failure
Adopt foundational GMDT early in the disease course
Postulate how ejection fraction will be used in future trials and in future guidelines
Review existing and forthcoming trial evidence on SGLT-2 inhibitors in HFpEF

The Advancing Management of Transthyretin Amyloidosis

Julian Gillmore Martha Grogan Laura Obici et al

1.00 EBAC

Published: 16/10/2023

To differentiate ATTR phenotypes based on presenting signs and symptoms.
To select appropriate tests to monitor symptomatic ATTR-cm from imaging, biomarker, functional and QoL assessments.
To recall how to identify disease progression across ATTR-cm.
To describe the different disease modifying treatments for ATTR including novel agents.

Heart Failure

Heart Failure Management in a Changing Paradigm

Andrew JS Coats Shelley Zieroth Javed Butler et al

1.00 EBAC

Published: 16/06/2022

Recall the utility of EF in heart failure treatment, patient selection and treatment response
Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
Incorporate quality of life measures for assessing therapeutic efficacy in HF
Recall outcomes from heart failure trials from recent congress and publications and their impact on practice

Medical Options for Advanced HFpEF/HFmrEF Patients: An Expert-Guided Virtual Ward Round

Biykem Bozkurt Muthiah Vaduganathan Pardeep Jhund

1.00 EBAC

Published: 22/10/2024

Describe the current limitations of HFmrEF/HFpEF GDMT in advanced patients
Select appropriate patients for advanced medical therapy
Recall recent trial data for novel therapeutic approaches
Use expert guidance to develop an evidence-based approach to managing advanced HFmrEF/HFpEF

Making Gains in HFpEF: An Appraisal of Where We Are Now

Shelley Zieroth Javed Butler Carolyn Lam

Not accredited

Published: 08/07/2022

Identify HFpEF patients who may benefit from being initiated on an SGLT-2 inhibitor
Recall current inertia rates amongst prescribers who manage heart failure
Adopt effective treatment strategies for HFpEF patients early in the disease course
Recall current guideline directed medical therapy options in HFpEF
Review clinical, real world and quality of life evidence for the use of SGLT-2 inhibitors in HFpEF

Heart Failure

Learning objectives

Learning objectives

Learning objectives

Heart Failure

Learning objectives

Learning objectives

Learning objectives

Heart Failure

Learning objectives

Learning objectives

Learning objectives